Authors: JD Doutremepuich ( ) , A Barbier ( ) , F Lacheretz ( )
Endotelon® (Procyanidolic Oligomers, Sanofi-Labaz Laboratories) are recognized "angioprotectors" for human venous insufficiency. Using an operative experimental model of lymphedema, we sought pharmacological evidence for potential lymphagogue activity of Endotelon®.
After surgical interruption of hindlimb lymphatics, rats developed for 7 days, peripheral edema that represented a mean 24% increase in volume compared to the nonoperated hindlimb (control). In this experimental counterpart of acute lymphedema, Endotelon® (400mg/kg/day p.o.) administered "prophylactically" (i.e., before, during, and 7 days after development of lymphedema) decreased rat hindlimb lymphedema by approximately 4.7%. When administered just before lymphedema became established (i.e., curatively), Endotelon® and Coumarin (another "angioprotector") failed to affect hindlimb edema.
These results suggest that Endotelon® may reduce or prevent postoperative acute edema.
How to Cite: Doutremepuich, J. , Barbier, A. & Lacheretz, F. (1991) “EFFECT OF ENDOTELON® (PROCYANIDOLIC OLIGOMERS) ON EXPERIMENTAL ACUTE LYMPHEDEMA OF THE RAT HINDLIMB”, Lymphology. 24(3).